Albemarle Q1 Net Sales Up 19%
Albemarle has posted a net income of $64.91m for the first quarter 2010, or $0.69 per diluted share, compared to $26.94m, or $0.28 per diluted share, for the
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.